Compagnie Lombard Odier S Cm A Crispr Therapeutics Ag Transaction History

Compagnie Lombard Odier S Cm A

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$61.1 - $83.78 $36,660 - $50,268	-600 Closed	0 $0
Q1 2022 Apr 27, 2022	SELL	$53.19 - $79.24 $58,509 - $87,164	-1,100 Reduced 64.71%	600 $38,000
Q4 2021 Feb 09, 2022	SELL	$70.09 - $111.29 $49,063 - $77,903	-700 Reduced 29.17%	1,700 $128,000
Q3 2021 Oct 28, 2021	BUY	$110.2 - $156.64 $11,020 - $15,663	100 Added 4.35%	2,400 $268,000
Q2 2021 Jul 15, 2021	BUY	$100.84 - $161.89 $153,781 - $246,882	1,525 Added 196.77%	2,300 $372,000
Q1 2021 Apr 23, 2021	BUY	$110.72 - $210.04 $41,520 - $78,765	375 Added 93.75%	775 $95,000
Q4 2020 Feb 09, 2021	BUY	$79.67 - $173.23 $31,868 - $69,292	400 New	400 $61,000
Q4 2018 Feb 13, 2019	SELL	$22.73 - $42.34 $18,184 - $33,872	-800 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$42.62 - $73.59 $34,096 - $58,872	800 New	800 $47,000

488

59M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.